Natco Pharma Profile
Key Indicators
- Authorised Capital ₹ 40.00 Cr
- Paid Up Capital ₹ 35.82 Cr
- Company Age 43 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 520.00 Cr
- Satisfied Charges ₹ 1,277.71 Cr
- Revenue Growth 30.83%
- Profit Growth 358.02%
- Ebitda 296.57%
- Net Worth 12.17%
- Total Assets 8.23%
About Natco Pharma
Natco Pharma Limited (NPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 19 September 1981 and has a history of 43 years and five months. Its registered office is in Hyderabad, Telangana, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524816 and on the National Stock Exchange(NSE) under NATCOPHARM.
The Corporate was formerly known as Natco Fine Pharmaceuticals Private Limited. The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 40.00 Cr and a paid-up capital of Rs 35.82 Cr.
The company currently has active open charges totaling ₹520.00 Cr. The company has closed loans amounting to ₹1,277.71 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Natco Pharma Limited India are S Rao as CFO and Venkat Chekuri as Company Secretary. Venkaiah Nannapaneni, Rajeev Nannapaneni, Agnihotra Chavali, and Seven other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L24230TG1981PLC003201
- Company No.
003201
- Stock Symbol
BSE : 524816 NSE : NATCOPHARM
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Sep 1981
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
What products or services does Natco Pharma Limited offer?
Natco Pharma Limited offers a wide range of products and services, including Common Disease Medicines, Steroid, Pain Relief Drugs & Pharmaceuticals, Pain Killers.
Who are the key members and board of directors at Natco Pharma?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkaiah Nannapaneni  | Managing Director | 01-Apr-2015 | Current |
| S Rao | CFO | 11-Feb-2016 | Current |
| Venkat Chekuri | Company Secretary | 01-Apr-2022 | Current |
Board Members (9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkateswara Thallapaka | Director | 18-Apr-2012 | Current |
Rajeev Nannapaneni  | Whole-Time Director | 30-Nov-2005 | Current |
| Agnihotra Chavali | Director | 23-Apr-2024 | Current |
| Umamaheshwarrao Madireddi | Director | 11-Feb-2015 | Current |
| Leela Digumarti | Director | 22-Sep-2014 | Current |
| Potluri Sivaramakrishna | Whole-Time Director | 12-Nov-2014 | Current |
Financial Performance of Natco Pharma.
Natco Pharma Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 30.83% increase. The company also saw a substantial improvement in profitability, with a 358.02% increase in profit. The company's net worth Soared by an impressive increase of 12.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Natco Pharma?
In 2022, Natco Pharma had a promoter holding of 48.81% and a public holding of 51.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Stci Primary Dealer LimitedVenkateswara Thallapaka is a mutual person
Mitcon Credentia Trusteeship Services LimitedVenkateswara Thallapaka is a mutual person
Bgse Financials LimitedVenkateswara Thallapaka is a mutual person
Kalyan Jewellers India LimitedAgnihotra Chavali is a mutual person
Pokarna LimitedAgnihotra Chavali is a mutual person
Indian Immunologicals LimitedAgnihotra Chavali is a mutual person
Charges (Loans)
₹520.00 Cr
₹1,277.71 Cr
Charges Breakdown by Lending Institutions
- Others : 520.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Mar 2011 | Others | ₹520.00 Cr | Open |
| 18 Oct 2016 | Others | ₹50.00 Cr | Satisfied |
| 22 Jun 2015 | Citi Bank N.A. | ₹12.05 Cr | Satisfied |
| 22 Dec 2014 | Citi Bank N.A. | ₹60.00 Cr | Satisfied |
| 10 May 2012 | Icici Bank Limited | ₹40.00 Cr | Satisfied |
How Many Employees Work at Natco Pharma?
Natco Pharma has a workforce of 4466 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Natco Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Natco Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
